Related Experiment Videos
The relaxin gene knockout mouse: a model of progressive scleroderma
Chrishan S Samuel1, Chongxin Zhao, Qing Yang
1Relaxin Group, Howard Florey Institute of Experimental Physiology & Medicine, The University of Melbourne, Victoria, Australia. c.samuel@hfi.unimelb.edu.au
The Journal of Investigative Dermatology
|September 28, 2005
Summary
Relaxin deficiency causes progressive skin fibrosis and thickening due to increased collagen. Early treatment with relaxin reversed these fibrotic changes in mice.
Area of Science:
- Dermatology
- Endocrinology
- Fibrosis Research
Background:
- Relaxin is a peptide hormone known for its anti-fibrotic effects.
- Understanding relaxin's role in skin aging and fibrosis is crucial for developing therapeutic strategies.
Purpose of the Study:
- To investigate the long-term effects of relaxin deficiency on skin structure and fibrosis.
- To evaluate the potential of relaxin therapy in reversing age-related dermal changes.
Main Methods:
- Comparison of skin from relaxin-deficient (RLX-/-) and normal (RLX+/+) mice using biochemical, histological, and MRI analyses.
- Assessment of collagen expression and distribution in skin biopsies at various ages.
- In vitro analysis of fibroblast collagen production and in vivo efficacy of recombinant human gene-2 (H2) relaxin treatment.
Main Results:
- Relaxin deficiency led to age-related dermal fibrosis and thickening in mice, with increased types I and III collagen.
- Elevated collagen deposition was evident from 1 month of age and affected dermal and hypodermal layers.
- Recombinant H2 relaxin treatment reversed fibrosis if applied early, but was ineffective on established scarring.
Conclusions:
- Relaxin plays a key role in regulating excessive collagen deposition and preventing dermal fibrosis.
- The relaxin-null mouse serves as a valuable model for studying progressive scleroderma.
- Targeted relaxin therapy may be effective for early-stage fibrotic skin diseases.